KR102405511B1 - Composition for skin regeneration, improvement or treatment damaged by ultraviolet light containing blackberry fermented product as an active ingredient - Google Patents
Composition for skin regeneration, improvement or treatment damaged by ultraviolet light containing blackberry fermented product as an active ingredient Download PDFInfo
- Publication number
- KR102405511B1 KR102405511B1 KR1020200013016A KR20200013016A KR102405511B1 KR 102405511 B1 KR102405511 B1 KR 102405511B1 KR 1020200013016 A KR1020200013016 A KR 1020200013016A KR 20200013016 A KR20200013016 A KR 20200013016A KR 102405511 B1 KR102405511 B1 KR 102405511B1
- Authority
- KR
- South Korea
- Prior art keywords
- blackberry
- fermented product
- skin
- uvb
- composition
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 29
- 239000004480 active ingredient Substances 0.000 title claims abstract description 14
- 230000006872 improvement Effects 0.000 title abstract description 7
- 230000036560 skin regeneration Effects 0.000 title abstract description 4
- 239000000284 extract Substances 0.000 claims abstract description 44
- 235000013305 food Nutrition 0.000 claims abstract description 11
- 230000037303 wrinkles Effects 0.000 claims abstract description 8
- 201000004624 Dermatitis Diseases 0.000 claims abstract description 7
- 230000003796 beauty Effects 0.000 claims abstract description 4
- 240000006024 Lactobacillus plantarum Species 0.000 claims description 26
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims description 26
- 229940072205 lactobacillus plantarum Drugs 0.000 claims description 26
- 230000036541 health Effects 0.000 claims description 13
- 235000013376 functional food Nutrition 0.000 claims description 8
- 230000000694 effects Effects 0.000 abstract description 16
- 239000003814 drug Substances 0.000 abstract description 8
- 238000011161 development Methods 0.000 abstract description 2
- 230000018109 developmental process Effects 0.000 abstract description 2
- 244000078534 Vaccinium myrtillus Species 0.000 description 112
- 235000021029 blackberry Nutrition 0.000 description 112
- 235000017848 Rubus fruticosus Nutrition 0.000 description 107
- 239000000047 product Substances 0.000 description 51
- 230000001965 increasing effect Effects 0.000 description 29
- 108010050808 Procollagen Proteins 0.000 description 26
- 210000003491 skin Anatomy 0.000 description 23
- 238000004519 manufacturing process Methods 0.000 description 21
- 241000699666 Mus <mouse, genus> Species 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 15
- 102000043136 MAP kinase family Human genes 0.000 description 14
- 108091054455 MAP kinase family Proteins 0.000 description 14
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 12
- 101000979342 Homo sapiens Nuclear factor NF-kappa-B p105 subunit Proteins 0.000 description 12
- 102100023050 Nuclear factor NF-kappa-B p105 subunit Human genes 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 230000002829 reductive effect Effects 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 9
- 238000000855 fermentation Methods 0.000 description 9
- 230000004151 fermentation Effects 0.000 description 9
- 239000008194 pharmaceutical composition Substances 0.000 description 9
- 230000026731 phosphorylation Effects 0.000 description 9
- 238000006366 phosphorylation reaction Methods 0.000 description 9
- 108010055717 JNK Mitogen-Activated Protein Kinases Proteins 0.000 description 8
- 239000012153 distilled water Substances 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 230000037380 skin damage Effects 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 8
- ZTOJFFHGPLIVKC-YAFCTCPESA-N (2e)-3-ethyl-2-[(z)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound S\1C2=CC(S(O)(=O)=O)=CC=C2N(CC)C/1=N/N=C1/SC2=CC(S(O)(=O)=O)=CC=C2N1CC ZTOJFFHGPLIVKC-YAFCTCPESA-N 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 238000010171 animal model Methods 0.000 description 7
- 230000003078 antioxidant effect Effects 0.000 description 7
- 230000003247 decreasing effect Effects 0.000 description 7
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 6
- 102000007665 Extracellular Signal-Regulated MAP Kinases Human genes 0.000 description 6
- 108010007457 Extracellular Signal-Regulated MAP Kinases Proteins 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 6
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 6
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 6
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 238000001262 western blot Methods 0.000 description 6
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 5
- 102100039337 NF-kappa-B inhibitor alpha Human genes 0.000 description 5
- 102000011779 Nitric Oxide Synthase Type II Human genes 0.000 description 5
- 108010076864 Nitric Oxide Synthase Type II Proteins 0.000 description 5
- 230000002292 Radical scavenging effect Effects 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 5
- 229960005070 ascorbic acid Drugs 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 229930003935 flavonoid Natural products 0.000 description 5
- 150000002215 flavonoids Chemical class 0.000 description 5
- 235000017173 flavonoids Nutrition 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 235000013355 food flavoring agent Nutrition 0.000 description 5
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 description 5
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 150000008442 polyphenolic compounds Chemical class 0.000 description 5
- 235000013824 polyphenols Nutrition 0.000 description 5
- 108010035532 Collagen Proteins 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- FVQOMEDMFUMIMO-UHFFFAOYSA-N Hyperosid Natural products OC1C(O)C(O)C(CO)OC1OC1C(=O)C2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 FVQOMEDMFUMIMO-UHFFFAOYSA-N 0.000 description 4
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 4
- 235000013361 beverage Nutrition 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- 210000002615 epidermis Anatomy 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 101710151806 72 kDa type IV collagenase Proteins 0.000 description 3
- 102100026802 72 kDa type IV collagenase Human genes 0.000 description 3
- 238000008157 ELISA kit Methods 0.000 description 3
- 239000002211 L-ascorbic acid Substances 0.000 description 3
- 235000000069 L-ascorbic acid Nutrition 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 108010052419 NF-KappaB Inhibitor alpha Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 244000299461 Theobroma cacao Species 0.000 description 3
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 3
- 239000000872 buffer Chemical group 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 235000013365 dairy product Nutrition 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000002055 immunohistochemical effect Effects 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 229930002330 retinoic acid Natural products 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 229960001727 tretinoin Drugs 0.000 description 3
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 3
- 230000037373 wrinkle formation Effects 0.000 description 3
- ZTOJFFHGPLIVKC-UHFFFAOYSA-N 3-ethyl-2-[(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound S1C2=CC(S(O)(=O)=O)=CC=C2N(CC)C1=NN=C1SC2=CC(S(O)(=O)=O)=CC=C2N1CC ZTOJFFHGPLIVKC-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 101001013150 Homo sapiens Interstitial collagenase Proteins 0.000 description 2
- 101000961071 Homo sapiens NF-kappa-B inhibitor alpha Proteins 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 239000002033 PVDF binder Substances 0.000 description 2
- 206010051246 Photodermatosis Diseases 0.000 description 2
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 2
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 2
- 208000000453 Skin Neoplasms Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 229960004308 acetylcysteine Drugs 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- 235000010208 anthocyanin Nutrition 0.000 description 2
- 239000004410 anthocyanin Substances 0.000 description 2
- 229930002877 anthocyanin Natural products 0.000 description 2
- 150000004636 anthocyanins Chemical class 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 238000011088 calibration curve Methods 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 235000019219 chocolate Nutrition 0.000 description 2
- 230000001120 cytoprotective effect Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 238000010195 expression analysis Methods 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- -1 pH adjusters Substances 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 230000008845 photoaging Effects 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- USHAGKDGDHPEEY-UHFFFAOYSA-L potassium persulfate Chemical compound [K+].[K+].[O-]S(=O)(=O)OOS([O-])(=O)=O USHAGKDGDHPEEY-UHFFFAOYSA-L 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 238000002203 pretreatment Methods 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 235000005875 quercetin Nutrition 0.000 description 2
- 229960001285 quercetin Drugs 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 230000009759 skin aging Effects 0.000 description 2
- 201000000849 skin cancer Diseases 0.000 description 2
- 210000001626 skin fibroblast Anatomy 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- GFTUVGXUYWIPMI-BHMOCAHYSA-N (2r,3s,4r,5r,6r)-2-(hydroxymethyl)-6-[(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydrochromen-2-yl)methyl]oxane-3,4,5-triol Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)C[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GFTUVGXUYWIPMI-BHMOCAHYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
- DGZQFLFZJOSWOR-UHFFFAOYSA-N 4,5-dimethyl-2-(2-phenylphenyl)-1,3-thiazole;1h-tetrazol-1-ium;bromide Chemical compound [Br-].[NH2+]1C=NN=N1.S1C(C)=C(C)N=C1C1=CC=CC=C1C1=CC=CC=C1 DGZQFLFZJOSWOR-UHFFFAOYSA-N 0.000 description 1
- RXGJTUSBYWCRBK-UHFFFAOYSA-M 5-methylphenazinium methyl sulfate Chemical compound COS([O-])(=O)=O.C1=CC=C2[N+](C)=C(C=CC=C3)C3=NC2=C1 RXGJTUSBYWCRBK-UHFFFAOYSA-M 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000018380 Chemical injury Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010014970 Ephelides Diseases 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-N Metaphosphoric acid Chemical compound OP(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-N 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 239000012083 RIPA buffer Substances 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 241000220222 Rosaceae Species 0.000 description 1
- 238000011804 SKH1 hairless mouse Methods 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- GLEVLJDDWXEYCO-UHFFFAOYSA-N Trolox Chemical compound O1C(C)(C(O)=O)CCC2=C1C(C)=C(C)C(O)=C2C GLEVLJDDWXEYCO-UHFFFAOYSA-N 0.000 description 1
- 241000219094 Vitaceae Species 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 229940064008 acai berry extract Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000012773 agricultural material Substances 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000003464 asthenopia Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 229940055416 blueberry extract Drugs 0.000 description 1
- 235000019216 blueberry extract Nutrition 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940096422 collagen type i Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 230000036566 epidermal hyperplasia Effects 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 235000020510 functional beverage Nutrition 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000005639 glycero group Chemical group 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 235000021021 grapes Nutrition 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 230000036732 histological change Effects 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
- 108010052968 leupeptin Proteins 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 230000002633 protecting effect Effects 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000010421 standard material Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 235000021012 strawberries Nutrition 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- IHIXIJGXTJIKRB-UHFFFAOYSA-N trisodium vanadate Chemical compound [Na+].[Na+].[Na+].[O-][V]([O-])([O-])=O IHIXIJGXTJIKRB-UHFFFAOYSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/065—Microorganisms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Polymers & Plastics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Botany (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Alternative & Traditional Medicine (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
본 발명은 블랙베리 발효물을 유효성분으로 함유하는 자외선에 의해 손상된 피부재생 및 개선 또는 치료용 조성물에 관한 것으로, 본 발명의 블랙베리 발효물은 자외선 조사에 의해 유발된 피부주름 및 염증을 억제하는 효과가 기존에 알려진 블랙베리 추출물 보다 현저하게 우수하므로, 자외선에 의한 피부주름 또는 피부염증 관련 이너뷰티 식품, 의약품 등 개발에 보다 유용하게 이용될 수 있다.The present invention relates to a composition for skin regeneration and improvement or treatment damaged by ultraviolet rays containing blackberry fermented product as an active ingredient. Since the effect is remarkably superior to the previously known blackberry extract, it can be used more usefully in the development of skin wrinkles or skin inflammation-related inner beauty food, pharmaceuticals, etc.
Description
본 발명은 블랙베리 발효물을 유효성분으로 함유하는 자외선에 의해 손상된 피부재생 및 개선 또는 치료용 조성물에 관한 것이다. The present invention relates to a composition for skin regeneration and improvement or treatment damaged by ultraviolet rays containing blackberry fermented product as an active ingredient.
피부는 신체의 가장 외부에 존재하는 기관으로 여러 가지 기능을 가짐과 동시에 외모 및 이미지 등에 큰 영향을 미치는 중요한 기관으로서, 사람에 따라 전체 중량의 약 3 내지 5kg을 차지하며, 다양한 세포들과 독특한 구조로 이루어져 신체의 외각 표면을 덮고 있어서 수분의 증발 방지, 체온조절, 자외선 등 외부 자극으로부터의 인체보호, 유해 미생물의 침입 방지 등 인체의 1차 방어막 역할을 수행하는 기관이라고 할 수 있다.The skin is the most external organ of the body, and at the same time has various functions and is an important organ that has a great influence on appearance and image. As it covers the outer surface of the body, it can be said to be an organ that plays the role of the body's primary defense barrier, such as preventing the evaporation of moisture, controlling body temperature, protecting the human body from external stimuli such as ultraviolet rays, and preventing the intrusion of harmful microorganisms.
또한, 피부는 물리, 화학적 상해, 세균이나 곰팡이 등의 미생물 및 기생충의 감염, 자외선에 의한 상해, 건조 등으로부터 인체를 보호하는 한편, 다양한 외부 자극에 대한 신경 수용체로서도 작용하고, 외부 항원을 인지하여 면역 세포를 제공하는 역할을 한다. 이러한 피부는 태양빛을 포함한 여러 가지 외부 요인에 의하여 손상받을 수 있다. 태양빛은 가시광선, 자외선 및 적외선으로 구성되는데 이 중 자외선은 체내에서 비타민 D를 합성하고, 살균작용을 하는 등 이로운 역할을 하는 동시에 피부노화, 피부암, 건조, 피부염, 잔주름, 기미, 주근깨 등을 생기게도 한다. 자외선은 파장길이에 따라 A, B, C의 3가지로 나뉘는데, 이 중 UVC는 오존층에서 차단되고, UVA와 UVB가 피부에 영향을 미친다. 특히 중파장의 자외선인 UVB(290~320nm)는 피부암의 발생, 면역시스템의 억제, 광노화(Photoaging) 등의 많은 부작용을 일으킨다.In addition, the skin protects the human body from physical and chemical injury, infection of microorganisms and parasites such as bacteria or fungi, injury by ultraviolet rays, drying, etc., while also acting as a nerve receptor for various external stimuli, and recognizes external antigens. It serves to provide immune cells. This skin can be damaged by various external factors including sunlight. Sunlight is composed of visible light, ultraviolet light, and infrared light. Among them, ultraviolet light plays a beneficial role such as synthesizing vitamin D in the body and sterilizing it, and at the same time, it prevents skin aging, skin cancer, dryness, dermatitis, fine lines, blemishes, and freckles. also make it happen UV rays are divided into three types, A, B, and C, depending on the wavelength. Among them, UVC is blocked by the ozone layer, and UVA and UVB affect the skin. In particular, UVB (290-320 nm), a medium-wavelength ultraviolet ray, causes many side effects such as skin cancer, suppression of the immune system, and photoaging.
한편, 블랙베리(black berry)는 쌍떡잎 식물 장미목 장미과 딸기속에 속하는 식물군으로 각종 비타민이 풍부하여 면역력을 높여줄 수 있고, 높은 비타민 A 함량으로 눈의 피로에 좋고, 식이섬유가 풍부하며, 안토시아닌이 풍부한 것으로 널리 알려져 있다. 특히, 블랙베리에 함유된 안토시아닌 중 C3G(Cyanidin-3-O-β-d-glucopyranoside)는 항산화 효과가 가장 뛰어난 물질로 알려져 있는데, C3G는 토코페롤(비타민 E)보다 노화 억제 효과가 5-7배나 강하며, 블랙베리의 C3G 최고 함량은 오디의 3배, 포도의 69배, 유색미의 6.9배에 달한다. C3G는 활성산소를 제거하여 뇌의 노화 및 신체의 노화를 예방시켜주며, 망막장애 치료 및 시력개선에도 효과가 있다. 또한 마우스 피부의 종양세포의 성장을 지연하고 인간 폐암 세포의 성장과 체내이행을 줄인다는 보고가 있다. On the other hand, black berry is a plant group belonging to the dicotyledonous plant Rosaceae Rosaceae and strawberries. It is rich in various vitamins and can enhance immunity. It is good for eyestrain with high vitamin A content, is rich in dietary fiber, and contains anthocyanins. It is widely known for its abundance. In particular, among the anthocyanins contained in blackberries, C3G (Cyanidin-3-O-β-d-glucopyranoside) is known to have the best antioxidant effect. It is strong, and the highest C3G content of blackberries is 3 times that of mulberry, 69 times that of grapes, and 6.9 times that of colored rice. C3G prevents brain aging and physical aging by removing free radicals, and is also effective in treating retinal disorders and improving eyesight. There is also a report that delays the growth of tumor cells in mouse skin and reduces the growth and migration of human lung cancer cells.
한편, 한국공개특허 제2019-0058091호에는 '블루베리 추출물을 함유하는 항염증용 조성물'을 개시하고 있으며, 한국공개특허 제2009-0105492호에는 '아사이베리 추출물을 유효성분으로 함유하는 미백 화장료 조성물'을 개시하고 있다. 하지만, 본 발명의 블랙베리 발효물을 유효성분으로 함유하는 자외선에 의해 손상된 피부재생 및 개선 또는 치료용 조성물에 대해 아직까지 개시된 바가 없다.On the other hand, Korean Patent Publication No. 2019-0058091 discloses 'Anti-inflammatory composition containing blueberry extract', and Korean Patent Publication No. 2009-0105492 discloses 'Whitening cosmetic composition containing acai berry extract as an active ingredient. ' is initiated. However, a composition for skin regeneration and improvement or treatment damaged by ultraviolet rays containing the blackberry fermented product of the present invention as an active ingredient has not yet been disclosed.
본 발명은 상기와 같은 요구에 의해 도출된 것으로서, 본 발명에서는 블랙베리 추출물에 락토바실러스 플랜타룸 JBMI F5(Lactobacillus plantarum JBMI F5, KACC91638P) 균주를 이용하여 발효물을 제조하였을 때, 발효 전의 블랙베리 추출물 보다 총 폴리페놀 및 총 플라보노이드의 함량이 증가하고 항산화 활성이 우수하였을 뿐만 아니라, 자외선에 의해 유도된 피부주름 및 피부염증에 대한 개선 효과가 현저하게 증가한 것을 확인함으로써, 본 발명을 완성하였다. The present invention was derived by the above requirements, and in the present invention, when a fermented product was prepared using a Lactobacillus plantarum JBMI F5 (KACC91638P) strain in a blackberry extract, blackberry extract before fermentation The present invention was completed by confirming that the content of total polyphenols and total flavonoids was increased and the antioxidant activity was excellent, and the improvement effect on skin wrinkles and skin inflammation induced by UV rays was significantly increased.
상기 과제를 해결하기 위하여, 또한, 본 발명은 블랙베리 발효물을 유효성분으로 함유하는 자외선에 의한 피부손상의 예방 또는 개선용 건강기능식품 조성물을 제공한다.In order to solve the above problems, the present invention also provides a health functional food composition for preventing or improving skin damage caused by ultraviolet rays containing blackberry fermented product as an active ingredient.
또한, 본 발명은 블랙베리 발효물을 유효성분으로 함유하는 자외선에 의한 염증의 예방 또는 치료용 약학 조성물을 제공한다.In addition, the present invention provides a pharmaceutical composition for preventing or treating inflammation caused by ultraviolet rays containing blackberry fermented product as an active ingredient.
본 발명의 블랙베리 발효물은 자외선 조사에 의해 유발된 피부주름 및 염증을 억제하는 효과가 기존에 알려진 블랙베리 추출물 보다 현저하게 우수하므로, 자외선에 의한 피부주름 또는 피부염증 관련 이너뷰티 식품, 의약품 등 개발에 보다 유용하게 이용될 수 있다.Since the blackberry fermented product of the present invention is significantly superior to the previously known blackberry extract in inhibiting skin wrinkles and inflammation induced by ultraviolet irradiation, inner beauty foods, pharmaceuticals, etc. It can be used more usefully for development.
도 1은 다양한 시료를 Hs68 세포에 전처리하고 UVB를 조사한 후 세포 생존율을 확인한 결과이다. Blank는 아무것도 처리하지 않은 군이며; Con은 UVB 단독 처리군이며; NAC는 N-아세틸시스테인(N-acetylcysteine)을 처리한 군이며; LP1 및 LP2는 락토바실러스 플란타룸 JBMI F5 균주 배양액(LP1: 1×107 CFU/㎖ 및 LP2: 5×107 CFU/㎖)을 처리한 군이며; BB1 및 BB2는 블랙베리 추출물을 각각 0.008 및 0.016mg/㎖을 처리한 군이며; BBL1 및 BBL2는 발효하지 않은 블랙베리 추출물과 락토바실러스 플란타룸 JBMI F5 균주 배양액의 혼합물(BBL1: 1×107 CFU/㎖ 및 BBL2: 5×107 CFU/㎖)을 처리한 군이며; 및 FBB1 및 FBB2는 블랙베리 추출물에 락토바실러스 플란타룸 JBMI F5 균주를 접종하여 제조된, JBMI F5 균주가 1×107 CFU/㎖ 및 5×107 CFU/㎖ 포함된 각 블랙베리 발효물을 처리한 군을 나타낸다.
도 2는 다양한 시료를 Hs68 세포에 전처리하고 UVB를 조사하였을 때, 프로콜라겐 타입 Ⅰ 및 MMP-1의 생성량을 ELISA로 분석한 결과이다. Blank는 증류수를 처리하고 UVB를 조사하지 않은 군이며, Con은 증류수를 처리하고 UVB를 조사한 군이며, NAC는 N-아세틸시스테인(N-acetylcysteine)을 처리하고 UVB를 조사한 군이며, LP는 락토바실러스 플란타룸 JBMI F5 균주 배양액을 처리하고 UBV를 조사한 군이며, BB는 블랙베리 추출물을 처리하고 UVB를 조사한 군이며, BBL은 블랙베리 추출물 및 락토바실러스 플란타룸 JBMI F5 균주 배양액 혼합물을 처리하고 UBV를 조사한 군이며, FBB는 블랙베리 추출물에 락토바실러스 플란타룸 JBMI F5 균주를 접종하여 발효된 블랙베리 발효물을 처리하고 UBV를 조사한 군을 의미한다.
도 3은 Hs68 세포에 블랙베리 발효물(FBB)을 전처리하고 UVB를 조사하였을 때, 프로콜라겐 및 MMPs의 발현 수준을 확인한 웨스턴 블롯 결과(A) 및 이를 정량화하여 나타낸 그래프(B)이다.
도 4는 Hs68 세포에 블랙베리 발효물(FBB)을 전처리하고 UVB를 조사하였을 때, MAPK(Mitogen-activated protein kinase) 및 NFκB(nuclear factor kappa light chain enhancer of activated B cell)의 인산화 수준 감소를 확인한 웨스턴 블롯 결과(A) 및 이를 정량화하여 나타낸 그래프(B)이다.
도 5는 동물모델 마우스에 본 발명의 블랙베리 발효물(FBB)을 식이하고 4주간 UVB를 조사하였을 때, 마우스 피부의 복제물(replica)의 주름 형성 정도를 나타낸 사진(A)과 H&E(hematoxylin-eosin) 염색을 통해 조직학적 변화를 나타낸 사진(B) 및 표피의 두께를 측정하여 나타낸 그래프(C)이다. CON은 증류수를 식이하고 UVB를 조사하지 않은 군이며, UVB는 증류수를 식이하고 UVB를 조사한 군이며, RA는 레티노산(retinoic acid)을 식이하고 UVB를 조사한 군이며, LP는 락토바실러스 플란타룸 JBMI F5 균주 배양액을 식이하고 UBV를 조사한 군이며, BB는 블랙베리 추출물을 식이하고 UVB를 조사한 군이며, BBL은 블랙베리 추출물 및 락토바실러스 플란타룸 JBMI F5 균주 배양액 혼합물을 식이하고 UBV를 조사한 군이며, FBB는 블랙베리 발효물을 식이하고 UBV를 조사한 군을 의미한다.
도 6은 동물모델 마우스에 본 발명의 블랙베리 발효물(FBB)을 식이하고 4주간 UVB를 조사하였을 때, 마우스의 혈청 및 조직에서 MMP-1(A) 및 프로콜라겐(B)의 생성량을 확인한 결과이다.
도 7은 동물모델 마우스에 본 발명의 블랙베리 발효물(FBB)을 식이하고 4주간 UVB를 조사하였을 때, MMP-1의 면역조직화학적 변화를 나타낸 사진(A)과 프로콜라겐 및 MMPs 단백질을 정량화하여 나타낸 그래프(B)이다.
도 8은 동물모델 마우스에 본 발명의 블랙베리 발효물(FBB)을 식이하고 4주간 UVB를 조사하였을 때, ERK(extracellular signal-regulated kinase), JNK(c-Jun N-terminal kinases) 및 p38 단백질의 인산화 수준 감소를 확인한 웨스턴 블롯 결과이다.
도 9는 동물모델 마우스에 본 발명의 블랙베리 발효물(FBB)을 식이하고 4주간 UVB를 조사하였을 때, iNOS(Inducible nitric oxide synthase) 및 COX-2(cyclooxygenase-2)의 발현 감소와 NFκB 및 IκBα(nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha)의 인산화 수준 감소를 확인한 웨스턴 블롯 결과이다.1 is a result of confirming the cell viability after pre-treating various samples to Hs68 cells and irradiating UVB. Blank is the group in which nothing was treated; Con is the UVB-only treatment group; NAC is a group treated with N-acetylcysteine; LP1 and LP2 are groups treated with Lactobacillus plantarum JBMI F5 strain culture medium (LP1: 1×10 7 CFU/ml and LP2: 5×10 7 CFU/ml); BB1 and BB2 are groups treated with blackberry extract at 0.008 and 0.016 mg/ml, respectively; BBL1 and BBL2 are a group treated with a mixture of unfermented blackberry extract and Lactobacillus plantarum JBMI F5 strain culture (BBL1: 1×10 7 CFU/ml and BBL2: 5×10 7 CFU/ml); And FBB1 and FBB2 are produced by inoculating the Lactobacillus plantarum JBMI F5 strain in the blackberry extract, each of the blackberry fermented products containing 1×10 7 CFU/ml and 5×10 7 CFU/ml of the JBMI F5 strain. The treated group is shown.
Figure 2 is a result of analyzing the production amount of procollagen type I and MMP-1 by ELISA when various samples were pretreated to Hs68 cells and irradiated with UVB. Blank is a group treated with distilled water and not irradiated with UVB, Con is a group treated with distilled water and irradiated with UVB, NAC is a group treated with N-acetylcysteine and irradiated with UVB, LP is Lactobacillus Plantarum JBMI F5 strain culture is treated and UBV is irradiated, BB is blackberry extract treated and UVB is irradiated, BBL is blackberry extract and Lactobacillus plantarum JBMI F5 strain culture mixture is treated and UBV is treated. , and FBB refers to a group in which blackberry extracts were inoculated with Lactobacillus plantarum JBMI F5 strain, processed blackberry fermented products, and UBV was irradiated.
3 is a Western blot result (A) confirming the expression levels of procollagen and MMPs when Hs68 cells were pretreated with blackberry ferment (FBB) and irradiated with UVB, and a graph (B) quantified and shown.
Figure 4 shows that when Hs68 cells were pretreated with fermented blackberries (FBB) and irradiated with UVB, phosphorylation levels of mitogen-activated protein kinase (MAPK) and nuclear factor kappa light chain enhancer of activated B cell (NFκB) were reduced. Western blot results (A) and graphs (B) showing quantification thereof.
5 is a photograph (A) and H&E (hematoxylin- eosin) is a photograph showing histological changes through staining (B) and a graph showing the thickness of the epidermis measured by (C). CON is a group fed distilled water and not irradiated with UVB, UVB is a group fed distilled water and irradiated with UVB, RA is a group fed with retinoic acid and irradiated with UVB, LP is Lactobacillus plantarum A group fed JBMI F5 strain culture and irradiated with UBV, BB was a group fed blackberry extract and irradiated with UVB, and BBL was a group fed blackberry extract and Lactobacillus plantarum JBMI F5 strain culture mixture and irradiated with UBV. , and FBB refers to the group that ate blackberry fermented product and irradiated with UBV.
6 shows the amount of MMP-1 (A) and procollagen (B) produced in the mouse serum and tissue when the blackberry fermented product (FBB) of the present invention was fed to an animal model mouse and irradiated with UVB for 4 weeks. is the result
7 is a photograph showing the immunohistochemical changes of MMP-1 (A) and quantification of procollagen and MMPs proteins when an animal model mouse was fed with the blackberry fermented product (FBB) of the present invention and irradiated with UVB for 4 weeks. This is the graph (B) shown.
8 is an animal model mouse fed with the blackberry fermented product (FBB) of the present invention and irradiated with UVB for 4 weeks, ERK (extracellular signal-regulated kinase), JNK (c-Jun N-terminal kinases) and p38 protein Western blot results confirming the decrease in phosphorylation level of
9 is an animal model mouse fed with the blackberry fermented product (FBB) of the present invention and irradiated with UVB for 4 weeks, iNOS (inducible nitric oxide synthase) and COX-2 (cyclooxygenase-2) expression decrease and These are Western blot results confirming the decrease in phosphorylation level of IκBα (nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha).
본 발명의 목적을 달성하기 위하여, 본 발명은 블랙베리 발효물을 유효성분으로 함유하는 자외선에 의한 피부손상의 예방 또는 개선용 건강기능식품 조성물을 제공한다.In order to achieve the object of the present invention, the present invention provides a health functional food composition for preventing or improving skin damage caused by ultraviolet rays containing blackberry fermented product as an active ingredient.
본 발명의 건강기능식품 조성물에서, 상기 자외선에 의한 피부손상은 피부주름 또는 피부염증일 수 있으나, 이에 제한되지 않는다.In the health functional food composition of the present invention, the skin damage caused by the ultraviolet rays may be skin wrinkles or skin inflammation, but is not limited thereto.
또한, 상기 자외선은 자외선-B일 수 있으나, 이에 제한되지 않는다.In addition, the UV light may be UV-B, but is not limited thereto.
또한, 상기 조성물은 이너뷰티(inner beauty) 식품인 것이 바람직하지만, 이에 제한되지 않는다.In addition, the composition is preferably an inner beauty food, but is not limited thereto.
본 발명에 따른 건강기능식품 조성물은 자외선에 의해 야기될 수 있는 세포사멸을 억제하고, 프로콜라겐 생성을 증가시키며, MMP(matrix metalloproteinase) 활성을 저해시키므로, 자외선에 의한 피부손상을 보호할 수 있다.Since the health functional food composition according to the present invention inhibits apoptosis that may be caused by ultraviolet rays, increases procollagen production, and inhibits matrix metalloproteinase (MMP) activity, it is possible to protect skin damage caused by ultraviolet rays.
또한, 상기 블랙베리 발효물은 블랙베리 추출물에 락토바실러스 플랜타룸 JBMI F5(Lactobacillus plantarum JBMI F5)(KACC91638P) 균주를 접종하여 제조되는 것일 수 있으나, 이에 제한되지 않는다. 상기 락토바실러스 플랜타룸 JBMI F5(Lactobacillus plantarum JBMI F5)(KACC91638P) 균주는 농업생명공학연구원에 2011년 3월 10일자로 기탁된 균주이다.In addition, the blackberry fermented product may be prepared by inoculating a blackberry extract with a Lactobacillus plantarum JBMI F5 (KACC91638P) strain, but is not limited thereto. The Lactobacillus plantarum JBMI F5 ( Lactobacillus plantarum JBMI F5) (KACC91638P) strain is a strain deposited with the Institute of Agricultural Biotechnology on March 10, 2011.
또한, 상기 블랙베리 발효물의 발효 조건은 32~42℃에서 4~15시간 동안 수행되는 것일 수 있으며, 바람직하게는 37℃에서 7시간 동안 수행되는 것일 수 있으나, 이에 제한되지 않는다.In addition, the fermentation conditions of the blackberry fermented product may be performed at 32 to 42° C. for 4 to 15 hours, and preferably, may be performed at 37° C. for 7 hours, but is not limited thereto.
또한, 블랙베리 발효물 제조에 사용된 블랙베리 추출물은 용매 추출, 물리적 추출, 효소적 추출 등의 다양한 추출법을 이용하여 추출할 수 있으나, 바람직하게는 물리적 추출 방법을 이용하여 추출한 것일 수 있으나, 이에 제한되지 않는다. 상기 추출방법은 유효성분이 파괴되지 않고, 블랙베리로부터 활성이 높은 블랙베리 발효물을 얻을 수 있다. In addition, the blackberry extract used to prepare the blackberry fermented product may be extracted using various extraction methods such as solvent extraction, physical extraction, and enzymatic extraction, but may preferably be extracted using a physical extraction method. not limited The extraction method does not destroy the active ingredient, and it is possible to obtain a blackberry fermented product with high activity from the blackberry.
또한, 상기 블랙베리 추출물은 추출처리에 의해 얻어지는 추출액, 추출액의 희석액 또는 농축액, 추출액을 건조하여 얻어지는 건조물, 또는 조정제물 또는 정제물 중 어느 하나를 포함하는 것으로 한다.In addition, the blackberry extract shall include any one of an extract obtained by extraction treatment, a diluted or concentrated solution of the extract, a dried product obtained by drying the extract, or a crude product or a purified product.
본 발명의 자외선에 의한 피부손상의 예방 또는 개선용 건강기능식품 조성물에서, 상기 식품의 종류에는 특별한 제한은 없다. 상기 물질을 첨가할 수 있는 식품의 예로는 드링크제, 육류, 소시지, 빵, 비스킷, 떡, 초콜릿, 캔디류, 스낵류, 과자류, 피자, 라면, 기타 면류, 껌류, 아이스크림류를 포함한 낙농제품, 각종 스프, 음료수, 알코올 음료 및 비타민 복합제, 유제품 및 유가공 제품 등이 있으며, 통상적인 의미에서의 건강기능식품을 모두 포함한다. 상기 건강기능식품은 분말, 과립, 환, 정제, 캡슐, 캔디, 시럽 및 음료 중에서 선택된 어느 하나의 제형으로 제조 또는 가공될 수 있으나, 이에 한정되지 않으며 법률에 따라 어떤 형태로든지 제조, 가공될 수 있다.In the health functional food composition for preventing or improving skin damage caused by ultraviolet rays of the present invention, the type of the food is not particularly limited. Examples of foods to which the above substances can be added include drinks, meat, sausage, bread, biscuits, rice cakes, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gums, dairy products including ice cream, various soups, There are beverages, alcoholic beverages, vitamin complexes, dairy products, and dairy products, and includes all health functional foods in the ordinary sense. The health functional food may be manufactured or processed in any one formulation selected from powder, granule, pill, tablet, capsule, candy, syrup and beverage, but is not limited thereto, and may be manufactured or processed in any form according to the law. .
본 발명의 블랙베리 발효물은 식품에 그대로 첨가하거나 다른 식품 또는 식품 성분과 함께 사용될 수 있고, 통상적인 방법에 따라 적절하게 사용될 수 있다. 유효 성분의 혼합량은 그의 사용 목적에 따라 적합하게 결정될 수 있다. 일반적으로, 건강식품 중의 상기 블랙베리 발효물의 양은 전체 식품 중량의 0.1 내지 90 중량부로 가할 수 있다. 그러나 건강 및 위생을 목적으로 하거나 또는 건강 조절을 목적으로 하는 장기간의 섭취의 경우에는 상기 양은 상기 범위 이하일 수 있으며, 안전성 면에서 아무런 문제가 없기 때문에 유효성분은 상기 범위 이상의 양으로도 사용될 수 있다.The blackberry fermented product of the present invention may be added to food as it is or used together with other food or food ingredients, and may be appropriately used according to a conventional method. The mixing amount of the active ingredient may be appropriately determined depending on the intended use thereof. In general, the amount of the blackberry fermented product in the health food may be added in an amount of 0.1 to 90 parts by weight based on the total weight of the food. However, in the case of long-term intake for health and hygiene or health control, the amount may be less than the above range, and since there is no problem in terms of safety, the active ingredient may be used in an amount above the above range.
본 발명의 건강 기능성 음료 조성물은 지시된 비율로 필수 성분으로서 상기 블랙베리 발효물 이외에 함유하는 다른 성분에는 특별한 제한이 없으며 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다. 상술한 천연 탄수화물의 예는 모노사카라이드, 예를 들어, 포도당, 과당 등; 디사카라이드, 예를 들어 말토스, 슈크로스 등; 및 폴리사카라이드, 예를 들어 덱스트린, 시클로덱스트린 등과 같은 통상적인 당, 및 자일리톨, 소르비톨, 에리트리톨 등의 당알콜이다. 상술한 것 이외의 향미제로서 천연 향미제(타우마틴, 스테비아 추출물(예를 들어 레바우디오시드 A, 글리시르히진등) 및 합성 향미제(사카린, 아스파르탐 등)를 유리하게 사용할 수 있다. The health functional beverage composition of the present invention is an essential ingredient in the indicated ratio, and there is no particular limitation on other ingredients contained in addition to the blackberry fermented product. have. Examples of the above-mentioned natural carbohydrates include monosaccharides such as glucose, fructose and the like; disaccharides such as maltose, sucrose and the like; and polysaccharides such as conventional sugars such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol. As flavoring agents other than those described above, natural flavoring agents (taumatin, stevia extract (eg, rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agents (saccharin, aspartame, etc.) can be advantageously used. .
상기 외에 본 발명의 블랙베리 발효물은 여러 가지 영양제, 비타민, 광물(전해질), 합성 풍미제 및 천연 풍미제 등의 풍미제, 착색제 및 중진제(치즈, 초콜릿 등), 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알코올, 탄산음료에 사용되는 탄산화제 등을 함유할 수 있다. 그 밖에 본 발명의 블랙베리 발효물은 천연 과일 쥬스 및 과일 쥬스 음료 및 야채 음료의 제조를 위한 과육을 함유할 수 있다. 이러한 성분은 독립적으로 또는 조합하여 사용할 수 있다. In addition to the above, the blackberry fermented product of the present invention contains various nutrients, vitamins, minerals (electrolytes), flavoring agents such as synthetic and natural flavoring agents, colorants and thickeners (cheese, chocolate, etc.), pectic acid and salts thereof, Alginic acid and its salts, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated beverages, and the like may be contained. In addition, the blackberry fermented product of the present invention may contain natural fruit juice and pulp for the production of fruit juice beverages and vegetable beverages. These components may be used independently or in combination.
또한, 본 발명은 블랙베리 발효물을 유효성분으로 함유하는 자외선에 의한 염증의 예방 또는 치료용 약학 조성물을 제공한다.In addition, the present invention provides a pharmaceutical composition for preventing or treating inflammation caused by ultraviolet rays containing blackberry fermented product as an active ingredient.
본 발명의 약학 조성물에서, 상기 염증은 피부 염증일 수 있으나, 이에 제한되지 않는다.In the pharmaceutical composition of the present invention, the inflammation may be skin inflammation, but is not limited thereto.
또한, 상기 블랙베리 발효물은 프로콜라겐 생성을 증가시키고, MMP(matrix metalloproteinase)의 활성을 저해하는 것일 수 있으나, 이에 제한되지 않는다.In addition, the fermented blackberry may increase procollagen production and inhibit the activity of matrix metalloproteinase (MMP), but is not limited thereto.
본 발명의 약학 조성물은 블랙베리 발효물 이외에, 약학적으로 허용 가능한 담체, 부형제 및 희석제를 추가로 포함하는 것이 바람직하지만, 이에 제한되지 않는다.The pharmaceutical composition of the present invention preferably further comprises a pharmaceutically acceptable carrier, excipient and diluent in addition to the blackberry ferment, but is not limited thereto.
본 발명의 블랙베리 발효물을 유효성분으로 포함하는 약학 조성물은 경구 또는 비경구의 여러 가지 제형일 수 있다.The pharmaceutical composition comprising the fermented blackberry of the present invention as an active ingredient may be in various oral or parenteral formulations.
제제화할 경우에는 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제된다. 경구투여를 위한 고형 제제에는 정제, 환제, 산제, 과립제, 캡슐제 등이 포함되며, 이러한 고형 제제는 하나 이상의 화합물에 적어도 하나 이상의 부형제 예를 들면, 전분, 탄산칼슘, 수크로오스(sucrose) 또는 락토오스(lactose), 젤라틴 등을 섞어 조제된다. 또한, 단순한 부형제 이외에 스테아린산 마그네슘, 탈크 등과 같은 윤활제들도 사용된다. 경구 투여를 위한 액상 제제로는 현탁제, 내용액제, 유제, 시럽제 등이 해당되는데 흔히 사용되는 단순 희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다. 비경구 투여를 위한 제제에는 멸균된 수용액, 비수성 용제, 현탁제, 유제, 동결건조제제, 좌제가 포함된다. 비수성 용제 및 현탁 용제로는 프로필렌글리콜(propylene glycol), 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 위텝솔(witepsol), 마크로골, 트윈tween) 61, 카카오지, 라우린지, 글리세로 젤라틴 등이 사용될 수 있다.In the case of formulation, it is prepared using commonly used diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrants, and surfactants. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc., and these solid preparations include at least one excipient in one or more compounds, for example, starch, calcium carbonate, sucrose or lactose ( lactose), gelatin, etc. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Liquid formulations for oral administration include suspensions, solutions, emulsions, syrups, etc. In addition to water and liquid paraffin, which are commonly used simple diluents, various excipients such as wetting agents, sweeteners, fragrances, and preservatives may be included. have. Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, freeze-dried preparations, and suppositories. As the non-aqueous solvent and the suspending solvent, propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate may be used. As the base of the suppository, witepsol, macrogol, tween 61, cacao butter, laurin, glycero gelatin, and the like can be used.
본 발명의 약학 조성물은 경구 또는 비경구로 투여될 수 있으며, 비경구 투여 시 피부 외용 방식을 선택하는 것이 바람직하지만, 이에 제한되지 않는다.The pharmaceutical composition of the present invention may be administered orally or parenterally, and it is preferable to select a skin external application method for parenteral administration, but is not limited thereto.
본 발명에 따른 약학 조성물은 약제학적으로 유효한 양으로 투여한다. 본 발명에 있어서, "약제학적으로 유효한 양"은 의학적 치료에 적용 가능한 합리적인 수혜/위험 비율로 질환을 치료하기에 충분한 양을 의미하며, 유효용량 수준은 환자의 질환의 종류, 중증도, 약물의 활성, 약물에 대한 민감도, 투여 시간, 투여 경로 및 배출 비율, 치료기간, 동시 사용되는 약물을 포함한 요소 및 기타 의학 분야에 잘 알려진 요소에 따라 결정될 수 있다. 본 발명의 약학 조성물은 개별 치료제로 투여하거나 다른 치료제와 병용하여 투여될 수 있고 종래의 치료제와는 순차적 또는 동시에 투여될 수 있으며, 단일 또는 다중 투여될 수 있다. 상기한 요소들을 모두 고려하여 부작용없이 최소한의 양으로 최대 효과를 얻을 수 있는 양을 투여하는 것이 중요하며, 이는 당업자에 의해 용이하게 결정될 수 있다.The pharmaceutical composition according to the present invention is administered in a pharmaceutically effective amount. In the present invention, "pharmaceutically effective amount" means an amount sufficient to treat a disease at a reasonable benefit/risk ratio applicable to medical treatment, and the effective dose level is the type, severity, and drug activity of the patient. , can be determined according to factors including sensitivity to drug, administration time, administration route and excretion rate, duration of treatment, concurrent drugs, and other factors well known in the medical field. The pharmaceutical composition of the present invention may be administered as an individual therapeutic agent or may be administered in combination with other therapeutic agents, may be administered sequentially or simultaneously with conventional therapeutic agents, and may be administered single or multiple. In consideration of all of the above factors, it is important to administer an amount that can obtain the maximum effect with a minimum amount without side effects, which can be easily determined by a person skilled in the art.
본 발명의 약학 조성물의 투여량은 환자의 체중, 연령, 성별, 건강상태, 식이, 투여시간, 투여방법, 배설률 및 질환의 중증도에 따라 그 범위가 다양하게 사용할 수 있다.The dosage of the pharmaceutical composition of the present invention can be used in various ranges depending on the patient's weight, age, sex, health status, diet, administration time, administration method, excretion rate and severity of disease.
이하, 실시예를 이용하여 본 발명을 더욱 상세하게 설명하고자 한다. 이들 실시예는 오로지 본 발명을 보다 구체적으로 설명하기 위한 것으로 본 발명의 범위가 이들에 의해 제한되지 않는다는 것은 당해 기술분야에서 통상의 지식을 가진 자에게 있어 자명한 것이다. Hereinafter, the present invention will be described in more detail using examples. These examples are only for illustrating the present invention in more detail, and it will be apparent to those of ordinary skill in the art that the scope of the present invention is not limited thereto.
재료 및 방법Materials and Methods
블랙베리 발효물 제조Blackberry Fermentation Manufacturing
블랙베리의 무게를 잰 후에 물을 첨가하여 블랙베리 함량이 66%(w/v)가 되도록 제조하고 마쇄기로 분쇄하여 블랙베리 추출물을 얻은 다음, 면포를 이용하여 여과하였다. 상기 여과한 블랙베리 추출물은 121℃에서 15분간 멸균처리하고 pH 6으로 조절한 후, 하룻동안 배양한 락토바실러스 플랜타룸 JBMI F5(Lactobacillus plantarum JBMI F5, KACC91638P) 균주 배양액 5%(6×109 CFU/㎖)를 접종하여 37℃에서 230 rpm으로 7시간 동안 발효시켜 블랙베리 발효물(이하 '시료'라 함)을 획득하였다. 획득한 블랙베리 발효물에 덱스트린을 첨가한 후 동결건조하였다. After the blackberries were weighed, water was added to prepare the blackberry content to be 66% (w/v), and the blackberry extract was obtained by grinding with a grinder, and then filtered using a cotton cloth. The filtered blackberry extract was sterilized at 121° C. for 15 minutes, adjusted to pH 6, and then cultured for one day in Lactobacillus plantarum JBMI F5 (KACC91638P)
총 폴리페놀(Total polyphenol) 함량Total polyphenol content
100mg의 시료에 2ℓ의 메탄올을 첨가하여 30℃에서 60분간 균질화하여 10분간 원심분리한 후 여과하여 상층액을 사용하였다. 상층액 100㎕에 500㎕의 3차 증류수와 50㎕의 폴린-시오칼투 시약을 혼합하여 상온에서 5분간 반응시킨 후 2%(w/v) 탄산나트륨 600㎕를 넣고 혼합하였다. 혼합물을 37℃의 암소에서 반응시킨 후 분광광도계를 이용하여 765nm에서 측정하였으며, 표준물질로 갈산(gallic acid; Sigma Chemical Co., St.Louis, MO, USA)을 이용하여 검량선을 작성하였고, 총 폴리페놀 함량은 건조 시료 1g에 대한 mg GAE(qgarllic acid equivalent)으로 나타내었다.2L of methanol was added to a 100 mg sample, homogenized at 30° C. for 60 minutes, centrifuged for 10 minutes, filtered, and the supernatant was used. In 100 μl of the supernatant, 500 μl of tertiary distilled water and 50 μl of Paulin-Siocaltu reagent were mixed, reacted at room temperature for 5 minutes, and then 600 μl of 2% (w/v) sodium carbonate was added and mixed. After the mixture was reacted in a dark place at 37°C, it was measured at 765 nm using a spectrophotometer, and a calibration curve was prepared using gallic acid (Sigma Chemical Co., St.Louis, MO, USA) as a standard material, and the total The polyphenol content was expressed as mg GAE (qgarllic acid equivalent) for 1 g of a dry sample.
총 플라보노이드(Total flavonoid) 함량Total flavonoid content
100mg의 시료에 2ℓ의 메탄올을 첨가하여 30℃에서 60분간 균질화하여 10분간 원심분리한 후 여과하여 상층액을 사용하였다. 상층액 1㎖ 및 10%(w/v) 염화알루미늄(AlCl3)을 동일 양으로 혼합한 후 상온에 5분간 반응시키고, 분광광도계를 이용하여 415nm에서 측정하였으며, 표준물질로 퀘세틴(qercetin, Sigma Chemical Co.)을 이용하여 검량선을 작성하였다. 플라보노이드 함량은 건조 시료 1g에 대한 mg QE(quercetin equivalent)으로 나타내었다.2L of methanol was added to a 100 mg sample, homogenized at 30° C. for 60 minutes, centrifuged for 10 minutes, filtered, and the supernatant was used. 1ml of the supernatant and 10% (w/v) aluminum chloride (AlCl 3 ) were mixed in the same amount and reacted at room temperature for 5 minutes, measured at 415 nm using a spectrophotometer, and quercetin (qercetin, A calibration curve was prepared using Sigma Chemical Co.). Flavonoid content was expressed as mg QE (quercetin equivalent) for 1 g of dry sample.
L-아스코르브산 함량L-Ascorbic Acid Content
L-아스코르브산(L-ascorbic acid) 함량은 Megazyme kit를 이용하여 측정하였다. 구체적으로, 100mg의 시료에 3%(w/v) 메타인산(metaphosphoric acid) 및 10mM EDTA(ethylenediaminetetraacetic acid)를 첨가하여 상온에서 60분간 균질화하여 10분간 원심분리한 후 여과한 상등액을 사용하였다. 10㎕의 시료에 152㎕의 3차 증류수 및 버퍼 1(첨가양을 기재바랍니다)을 혼합하고 3분 후 MTT[3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide] 버퍼 2를 넣고 3분간 반응시켰으며, 분광광도계를 이용하여 578nm에서 1차 흡광도(A1)를 측정하고, PMS(5-methylphenazinium methyl sulfate) 버퍼를 넣고 8분 동안 반응시킨 후 578nm에서 2차 흡광도(A2)를 측정하였다. L-ascorbic acid (L-ascorbic acid) content was measured using a Megazyme kit. Specifically, 3% (w/v) metaphosphoric acid and 10 mM EDTA (ethylenediaminetetraacetic acid) were added to a 100 mg sample, homogenized at room temperature for 60 minutes, centrifuged for 10 minutes, and then filtered supernatant was used. Mix 152 μl of tertiary distilled water and buffer 1 (please indicate the amount to be added) to 10 μl of sample, and after 3 minutes, MTT[3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide]
항산화 활성antioxidant activity
DPPH(2,2-Diphenyl-1-picrylhydrazyl) 분석은 20㎕의 시료와 80㎕의 DPPH(2,2-Diphenyl-1-picrylhydrazyl, Sigma-Aldrich, St Louis, MO, USA) 용액을 96-웰 플레이트에 혼합하여 암소에서 30분간 실온에 반응시킨 후, 분광광도계(Multiskan ELISA, Thermo scientific Co. Ltd)를 이용하여 517nm에서 측정하였다. 양성대조군으로 아스코르브산(Ascorbic acid, Sigma-Aldrich)을 사용하였다.DPPH (2,2-Diphenyl-1-picrylhydrazyl) analysis is 20 μl of sample and 80 μl of DPPH (2,2-Diphenyl-1-picrylhydrazyl, Sigma-Aldrich, St Louis, MO, USA) solution were mixed in a 96-well plate and reacted in the dark for 30 minutes at room temperature, It was measured at 517 nm using a spectrophotometer (Multiskan ELISA, Thermo scientific Co. Ltd). Ascorbic acid (Sigma-Aldrich) was used as a positive control.
ABTS(2,2'-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid)) 분석은 80mM ABTS 용액과 30mM 과황산칼륨(Potassium persulfate, K2S2O8) 용액을 혼합하여 30℃의 암소에서 약 1시간 반응 시킨 후 734nm에서 흡광도가 1±0.1이 되도록 희석한 ABTS 용액을 사용하였다. 반응시킨 ABTS 희석용액 90㎕와 각 농도별 시료 10㎕를 혼합하여 37℃의 암소에서 30분간 반응시켜 734nm에서 흡광도를 측정하였으며, 양성대조군은 수용성 비타민 E 유도체인 Trolox®(Sigma-Aldirch)를 사용하였다.ABTS (2,2'-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid)) analysis was 80mM ABTS solution and 30mM potassium persulfate (Potassium persulfate, K 2 S 2 O 8 ) solution were mixed and reacted in a dark place at 30 ° C for about 1 hour, and then the diluted ABTS solution was used so that the absorbance at 734 nm was 1 ± 0.1. . 90 μl of the reacted diluted ABTS solution and 10 μl of each concentration sample were mixed and reacted for 30 minutes in a dark place at 37°C to measure absorbance at 734 nm. As a positive control, Trolox ® (Sigma-Aldirch), a water-soluble vitamin E derivative, was used. did
피부섬유아세포 배양 Skin fibroblast culture
인간 피부 섬유아세포주 Hs68를 DMEM(Dulbecco's modified Eagle medium, Gibco, Grand Isaland, NY)에 10%(v/v) FBS(fetal bovine serum, Gibco, Grand Isaland, NY) 및 1% 페니실린을 첨가한 후, 37℃ 및 5% CO2의 배양기에서 배양하였다. 계대배양은 4~5일 간격으로 배양하여 유지하였다.Human skin fibroblast line Hs68 was added to DMEM (Dulbecco's modified Eagle medium, Gibco, Grand Isaland, NY) with 10% (v/v) fetal bovine serum, Gibco, Grand Isaland, NY) and 1% penicillin. , 37° C. and 5% CO 2 , and incubated in an incubator. Subcultures were maintained by culturing at intervals of 4 to 5 days.
세포보호효과 평가Cell protective effect evaluation
Hs68 세포에서 블랙베리 발효물의 세포보호효과를 분석하기 위하여 MTT(3-(4,5-dimethylthiazole-2-yl)-2,5-biphenyl tetrazolium bromide) 분석법을 이용하여 분석하였다. 1×104 cells/㎖의 세포를 96 웰 세포 배양용기에 분주하여 24시간 동안 안정화시킨 후, 혈청이 결핍된 DMEM 배지로 24시간 동안 배양하여 세포주기를 동일화하였다. 블랙베리 발효물의 농도별(락토바실러스 플랜타룸 JBMI F5 균주가 1×107 CFU/㎖ 포함 또는 5×107 CFU/㎖ 포함)로 24시간 처리한 후, PBS로 두 번 세척한 후 소량의 PBS를 넣고 UV crosslinker(Analytik Jena AG, Jena, Germany)를 이용하여 UVB 100 mJ/㎠를 조사하였다. 자외선 조사 후 세포에 혈청이 결핍된 DMEM 배지를 넣어 주고 24시간 동안 배양시켰다. 대조군(Blank) 세포는 UVB 조사만 없이 같은 배지 조건에 노출되었다. 5mg/㎖의 MTT 시약을 각 웰에 넣고 4시간 동안 배양한 후 상등액을 제거하고 100㎖의 DMSO(dimethyl sulfoxide)를 첨가하여 포르마잔 결정체를 용해시킨 후, microplate reader를 이용하여 590nm에서 흡광도를 측정하였다.To analyze the cytoprotective effect of fermented blackberries on Hs68 cells, the MTT (3-(4,5-dimethylthiazole-2-yl)-2,5-biphenyl tetrazolium bromide) assay was used. Cells at 1×10 4 cells/ml were dispensed into a 96-well cell culture vessel and stabilized for 24 hours, and then cultured in serum-deficient DMEM medium for 24 hours to equalize the cell cycle. After 24 hours of treatment with each concentration of blackberry fermented product (Lactobacillus plantarum JBMI F5 strain contains 1×10 7 CFU/ml or 5×10 7 CFU/ml), washed twice with PBS, and then a small amount of PBS and
실험동물laboratory animal
6주령의 웅성 SKH-1 무모 마우스(20-24 g)는 (주)Samtaco(Osan, Korea)로부터 구입하였다. 마우스는 케이지 당 3마리씩 무작위로 나누고 12시간 낮/밤 주기로 하여 온도는 22±2℃ 및 습도는 55±5% 조건에서 사육하였다. 마우스는 실험 시작 전 일주일 동안 주위 환경에 적응시켰으며, 음식과 물을 자유롭게 섭취하도록 하였다. 동물 실험에 대한 모든 과정은 (재)전주농생명소재연구원 실험 동물 관리 위원회에서 검토 및 승인되었으며, 동물실험윤리위원회(IACUC) 지침을 엄격히 준수하였다. 일주일의 적응 기간이 지난 후, 마우스를 각 군에 6 마리씩 7 군으로 분리하였다. Blank는 증류수를 식이하고 UVB를 조사하지 않은 그룹이며, Con은 증류수를 식이하고 UVB를 조사한 그룹이며, NAC는 레티노산(retinoic acid)을 식이하고 UVB를 조사한 그룹이며, LP는 락토바실러스 플란타룸 JBMI F5 균주 배양액을 식이하고 UBV를 조사한 그룹이며, BB는 블랙베리 추출물을 식이하고 UVB를 조사한 그룹이며, BBL은 블랙베리 추출물 및 락토바실러스 플란타룸 JBMI F5 균주 배양액 혼합물을 식이하고 UBV를 조사한 그룹이며, FBB는 블랙베리 발효물을 식이하고 UBV를 조사한 그룹을 의미한다. 각각의 군은 하기 표 1에 개시한 바와 같이 UVB 조사 30분 전에 상기 시료들을 경구투여하였다. 6-week-old male SKH-1 hairless mice (20-24 g) were purchased from Samtaco (Osan, Korea). Mice were randomly divided into 3 mice per cage and bred at a temperature of 22±2° C. and a humidity of 55±5% with a 12-hour day/night cycle. Mice were acclimatized to the surrounding environment for a week before the start of the experiment, and allowed to freely consume food and water. All procedures for animal experiments were reviewed and approved by the Experimental Animal Management Committee of the Jeonju Agricultural and Biomaterials Research Institute, and the guidelines of the Animal Experimental Ethics Committee (IACUC) were strictly followed. After one week of adaptation period, mice were divided into 7 groups, 6 mice in each group. Blank is a group fed with distilled water and not irradiated with UVB, Con is a group fed with distilled water and irradiated with UVB, NAC is a group fed with retinoic acid and irradiated with UVB, LP is Lactobacillus plantarum A group fed JBMI F5 strain culture and irradiated with UBV, BB was a group fed blackberry extract and irradiated with UVB, and BBL was a group fed blackberry extract and Lactobacillus plantarum JBMI F5 strain culture mixture and irradiated with UBV. , and FBB refers to the group that ate blackberry fermented product and investigated UBV. Each group was orally administered with the
UVB 조사 UVB irradiation
자외선 조사에 의한 피부손상 동물 모델의 제작을 위해, UV 램프 장치(Waldmann Medizintechnik, Schwenningen, Germany)를 사용하였다. 마우스는 첫 주 동안에는 30 mJ/cm2, 두 번째 주는 60 mJ/cm2, 세 번째 주는 90 mJ/cm2, 마지막 주는 120 mJ/cm2의 조사량으로 매일 1회 UVB에 노출시켰다. 대조군은 자외선을 조사하지 않았으며, 마지막 조사 후 24시간 후에 SILFLO(Silflo, J&S Davis Ltd, UK)를 사용하여 마우스의 등쪽 피부 주름의 복제 이미지를 촬영하였고, 마우스의 중앙 등쪽으로부터 피부 조직을 채취하였다. For the production of an animal model of skin damage by UV irradiation, a UV lamp device (Waldmann Medizintechnik, Schwenningen, Germany) was used. Mice were exposed to UVB once daily at 30 mJ/cm 2 for the first week, 60 mJ/cm 2 for the second week, 90 mJ/cm 2 for the third week, and 120 mJ/cm 2 for the last week. The control group was not irradiated with ultraviolet rays, and 24 hours after the last irradiation, using SILFLO (Silflo, J&S Davis Ltd, UK), a duplicate image of the dorsal skin folds of the mouse was taken, and the skin tissue was collected from the central dorsal side of the mouse. .
프로콜라겐 타입 I 및 MMP-1 생성량 분석Analysis of procollagen type I and MMP-1 production amount
프로콜라겐(Procollagen)은 콜라겐의 구성성분으로 섬유아세포(fibroblast)에서 합성되며 피부 결합력과 탄력성에 연관이 있다. MMP-1(Matrix metalloproteinases-1)은 피부노화와 연관이 있으며 자외선에 의해 증가하는 것으로 알려져 있다. 본 발명에서는 자외선에 의한 감소된 프로콜라겐 타입 I(procollagen type I)과 증가된 MMP-1에 대한 블랙베리 발효물 효능을 조사하기 위해, 인간 섬유아세포 배양액의 상층액을 대상으로 Human MMP-1 및 Human Pro-Collagen Type I ELISA 키트(Abcam, Cambridge, UK)를 사용하여 프로콜라겐 타입 I 및 MMP-1의 생성량 변화를 확인하였고, 마우스의 혈액 및 피부조직을 대상으로 MMP-1(CUSABIO, Wuhan, China) 및 프로콜라겐 타입 I(Abcam, Cambridge, UK) ELISA 키트를 사용하여 프로콜라겐 타입 I 및 MMP-1의 생성량 변화를 확인하였다. 혈액은 3,000 rpm에서 15분간 원심분리한 후, 12,000 rpm에서 10분간 원심분리하여 혈청을 분리하였으며, 피부 조직은 균질기(homogenizer)를 사용하여 균질화한 다음, 4℃에서 12,000 rpm으로 20분간 원심분리하여 상등액을 분리하였다. 실험은 제조사의 지침에 따라 실시하였다.Procollagen is a component of collagen, synthesized in fibroblasts, and is related to skin adhesion and elasticity. Matrix metalloproteinases-1 (MMP-1) is associated with skin aging and is known to be increased by UV rays. In the present invention, in order to investigate the efficacy of blackberry fermented product for reduced procollagen type I and increased MMP-1 by ultraviolet light, human MMP-1 and human MMP-1 and Changes in the production amount of procollagen type I and MMP-1 were confirmed using the Human Pro-Collagen Type I ELISA kit (Abcam, Cambridge, UK), and MMP-1 (CUSABIO, Wuhan, China) and procollagen type I (Abcam, Cambridge, UK) ELISA kits were used to confirm the change in production amount of procollagen type I and MMP-1. The blood was centrifuged at 3,000 rpm for 15 minutes and then centrifuged at 12,000 rpm for 10 minutes to separate the serum, and the skin tissue was homogenized using a homogenizer, and then centrifuged at 4°C at 12,000 rpm for 20 minutes to separate the supernatant. The experiment was performed according to the manufacturer's instructions.
단백질 발현 분석Protein Expression Analysis
Hs68 세포주 및 마우스 피부조직에 차가운 RIPA 버퍼(10mM Tris-HCl, pH 7.5, 0.1%(v/v) NP-40, 0.5% sodium deoxycholate, 0.1%(w/v) SDS, 1mM sodium orthovanadate, 120mM sodium chloride, 1mM phenylmethylsulfonyl fluoride, 10g/mL leupeptin 및 1g/mL aprotinin)를 넣어 용해시킨 후 10,000 xg에서 10분간 원심분리하여 상등액을 분리하였다. 단백질을 SDS-폴리아크릴아미드 겔을 사용하여 전기영동 후 PVDF(Polyvinylidene fluoride) 멤브레인(Bio-Rad Lab., Hercules, CA, USA)에 트랜스퍼하였다. 5% 스킴 밀크(0.1% Tween 20 containing PBS, PBST) 용액에서 1시간 동안 비특이적 결합 부위를 블로킹한 뒤 1차 항체[anti-iNOS, COX-2, MAPK, NFκB, IκBα, MMPs, COLs(Cell Signaling, Beverly, MA)]로 하룻동안 배양하고 2차 항체[anti-rabbit IgG or anti-mouse IgG linked with horseradish peroxidase, (SantaCruz Biotechnology, Inc. USA)]로 상온에서 2시간 배양한 후 ECL 용액을 이용하여 amersham imager 600(GE Healthcare, Buckinghamshire, UK)으로 단백질 발현량을 측정하였다.Cold RIPA buffer (10mM Tris-HCl, pH 7.5, 0.1%(v/v) NP-40, 0.5% sodium deoxycholate, 0.1%(w/v) SDS, 1mM sodium orthovanadate, 120mM sodium in Hs68 cell line and mouse skin tissue chloride, 1 mM phenylmethylsulfonyl fluoride, 10 g/mL leupeptin, and 1 g/mL aprotinin) were added and dissolved, and the supernatant was separated by centrifugation at 10,000 x g for 10 minutes. Proteins were transferred to a polyvinylidene fluoride (PVDF) membrane (Bio-Rad Lab., Hercules, CA, USA) after electrophoresis using SDS-polyacrylamide gel. After blocking non-specific binding sites in 5% skim milk (0.1
면역조직화학적 검사Immunohistochemical test
UV 조사된 마우스의 등쪽 피부 조직을 4% 파라포름알데히드에 24시간 동안 고정시킨 다음 파라핀에 포매시켰다. 파라핀 블럭을 cryotome을 이용하여 슬라이싱한 후, 조직 절편을 슬라이드 위에 올려 놓고 H&E(Hematoxylin and eosin), MT(Masson's trichrome) 및 마우스 MMP-1 항체(Abcam, Cambridge, UK)로 염색하였다. H&E 염색은 일반적인 조직 병리학적 변화와 표피의 두께를 평가하기 위해 사용하였고, MT 염색은 콜라겐 섬유의 변화 정도를 측정하기 위해 사용하였다. 염색된 조직 슬라이드는 광학 현미경(Olympus, Tokyo, Japan)을 사용하여 관찰하고 촬영하였다. UV 조사된 마우스 피부조직에서 표피 과다 증식을 평가하기 위해 200×배율(H&E 염색)로 슬라이드 당 5개를 임의로 선택된 위치에서 표피의 수직 두께를 측정하였다. 데이터는 이미지 분석 프로그램인 Image J 1.52(Wayne Rasband, National Institutes of Health, Bethesda, MD, USA)를 통해 평가하였다.The dorsal skin tissues of UV-irradiated mice were fixed in 4% paraformaldehyde for 24 hours and then embedded in paraffin. After slicing the paraffin block using a cryotome, the tissue section was placed on the slide and stained with H&E (Hematoxylin and eosin), MT (Masson's trichrome) and mouse MMP-1 antibody (Abcam, Cambridge, UK). H&E staining was used to evaluate general histopathological changes and epidermal thickness, and MT staining was used to measure the degree of change in collagen fibers. The stained tissue slides were observed and photographed using an optical microscope (Olympus, Tokyo, Japan). In order to evaluate the epidermal hyperplasia in UV-irradiated mouse skin tissue, the vertical thickness of the epidermis was measured at 200× magnification (H&E staining) at 5 randomly selected positions per slide. Data were evaluated through Image J 1.52 (Wayne Rasband, National Institutes of Health, Bethesda, MD, USA), an image analysis program.
실시예 1. 블랙베리 발효물의 생리활성물질 함량 및 항산화 활성 증가Example 1. Increased content of physiologically active substances and antioxidant activity of blackberry fermented product
블랙베리 추출물 및 이를 락토바실러스 플랜타룸 JBMI F5 균주를 이용하여 제조한 블랙베리 발효물을 대상으로 생리활성물질 함량 및 항산화 활성을 측정하였다. 그 결과, 하기 표 2에 개시한 바와 같이 블랙베리 추출물에 락토바실러스 플랜타룸 JBMI F5 균주를 접종하여 발효물을 제조하였을 때, 블랙베리 추출물 및 블랙베리 추출물과 락토바실러스 플란타룸 JBMI F5 균주 배양액의 혼합물(발효하지 않음)에 비해 총 폴리페놀 함량(TPC, total polyphenol content), 총 플라보노이드 함량(TFC, total flavonoid content) 및 비타민 함량(VC, Vitamin C)이 현저하게 증가하였으며, DPPH(2,2-Diphenyl-1-picrylhydrazyl) 및 ABTS(2,2'-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid)) 라디칼 소거활성도 현저하게 증가한 것을 확인할 수 있었다. 상기 결과를 통해, 블랙베리 추출물을 락토바실러스 플란타룸 JBMI F5 균주를 접종하여 발효함에 따라 생리활성물질 함량 및 항산화 활성이 현저하게 증가된다는 것을 알 수 있었다.The content of physiologically active substances and antioxidant activity were measured for the blackberry extract and the blackberry fermented product prepared using the Lactobacillus plantarum JBMI F5 strain. As a result, as shown in Table 2 below, when the blackberry extract was inoculated with the Lactobacillus plantarum JBMI F5 strain to prepare a fermented product, the culture of the blackberry extract and the blackberry extract and the Lactobacillus plantarum JBMI F5 strain was The total polyphenol content (TPC, total polyphenol content), total flavonoid content (TFC, total flavonoid content) and vitamin content (VC, Vitamin C) were significantly increased compared to the mixture (unfermented), and DPPH (2,2 -Diphenyl-1-picrylhydrazyl) and ABTS (2,2'-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid)) radical scavenging activity were also significantly increased. Through the above results, it was found that the content of bioactive substances and antioxidant activity were remarkably increased as the blackberry extract was inoculated with Lactobacillus plantarum JBMI F5 strain and fermented.
소거활성(%)DPPH radical
Scavenging activity (%)
소거활성(%)ABTS radical
Scavenging activity (%)
BB는 블랙베리 추출물; BBL은 블랙베리 추출물 및 락토바실러스 플란타룸 JBMI F5 균주 배양액 혼합물(발효하지 않음); FBB는 블랙베리 추출물에 락토바실러스 플란타룸 JBMI F5 균주를 접종하여 제조된 블랙베리 발효물; AA는 아스코르브산(ascorbic acid)이며, ***; 블랙베리 추출물에 비해 TPC, TFC, VC, DPPH 라디칼 소거활성 또는 ABTS 라디칼 소거활성 증가 효과가 통계적으로 유의하다는 것을 의미하며 p 값이 0.001 미만인 것을 의미한다.BB is blackberry extract; BBL is a mixture of blackberry extract and Lactobacillus plantarum JBMI F5 strain culture (not fermented); FBB is a blackberry fermented product prepared by inoculating a Lactobacillus plantarum JBMI F5 strain into a blackberry extract; AA is ascorbic acid, ***; Compared to blackberry extract, it means that the effect of increasing TPC, TFC, VC, DPPH radical scavenging activity or ABTS radical scavenging activity is statistically significant, meaning that the p value is less than 0.001.
실시예 2. 블랙베리 발효물의 세포보호효과Example 2. Cell protective effect of fermented blackberry
블랙베리 추출물에 락토바실러스 플란타룸 JBMI F5 균주를 접종하여 제조한 블랙베리 발효물의 보호효과를 확인하기 위해, 블랙베리 발효물을 Hs68 세포에 전처리하고 UVB를 조사한 후 MTT 분석을 수행하였다. 그 결과, 도 1에 개시한 바와 같이 UVB 단독 처리군(Con)에서 세포 생존율이 감소한 반면, 블랙베리 발효물을 처리한 모든 군에서 세포 생존율이 유지되어 자외선으로부터 세포보호 효과가 있다는 것을 확인하였다. 따라서 본 발명은 블랙베리 발효물(JBMI F5 균주가 1×107 CFU/㎖ 포함)을 대상으로 하기 실시예를 실시하였다.In order to confirm the protective effect of the blackberry fermented product prepared by inoculating the blackberry extract with the Lactobacillus plantarum JBMI F5 strain, the blackberry fermented product was pre-treated to Hs68 cells, irradiated with UVB, and then MTT analysis was performed. As a result, as shown in Figure 1, the cell viability decreased in the UVB-only treatment group (Con), while the cell viability was maintained in all groups treated with the blackberry fermented product, confirming that there was a cytoprotective effect from UVB rays. Therefore, in the present invention, the following examples were performed on blackberry fermented product (JBMI F5 strain included 1×10 7 CFU/ml).
실시예 3. 블랙베리 발효물 처리에 따른 프로콜라겐 및 MMPs의 생성량 변화 분석Example 3. Analysis of changes in production amount of procollagen and MMPs according to blackberry fermentation
자외선 조사에 의한 피부손상에서 프로콜라겐(procollagen)의 생성 억제와 MMPs(Matrix metallopeptidases)의 발현 증가는 하나의 표적인자로 알려져 있다. 따라서 Hs68 세포를 대상으로 UVB 조사에 의해 유도되는 프로콜라겐의 생성 억제와 MMPs의 발현 증가에 대한 블랙베리 발효물의 효능을 확인하였다. 그 결과, 도 2에 개시한 바와 같이 UVB 조사에 의해 프로콜라겐 타입 Ⅰ의 생성이 억제되고 MMP-1의 생성이 증가된 반면, 블랙베리 발효물을 전처리하고 UVB를 조사한 경우에 프로콜라겐 타입 Ⅰ의 생성이 증가되고, MMP-1의 생성이 감소되었을 뿐만 아니라 블랙베리 추출물과 비교하였을 때 프로콜라겐 타입 Ⅰ의 생성 및 MMP-1의 감소 정도에서 유의한 차이가 있다는 것을 알 수 있었다. 또한, 단백질 발현 분석 결과에서도 마찬가지로 블랙베리 발효물을 전처리함으로써 UVB 조사로 인해 감소하였던 콜라겐 Ⅰ 및 Ⅲ의 발현이 증가되고, UVB 조사로 인해 증가하였던 MMP-1 및 MMP-2의 발현이 감소되는 것을 알 수 있었다(도 3).Inhibition of procollagen production and increased expression of matrix metallopeptidases (MMPs) in skin damage caused by UV irradiation are known as target markers. Therefore, the efficacy of the blackberry fermented product for suppressing the production of procollagen induced by UVB irradiation and increasing the expression of MMPs in Hs68 cells was confirmed. As a result, as shown in FIG. 2, the production of procollagen type I was inhibited by UVB irradiation and the production of MMP-1 was increased, whereas when the blackberry fermented product was pre-treated and irradiated with UVB, the production of procollagen type I was It was found that the production was increased and the production of MMP-1 was decreased, and there was a significant difference in the production of procollagen type I and the degree of reduction of MMP-1 when compared with the blackberry extract. In addition, in the protein expression analysis results, it was found that the expression of collagen I and III, which was decreased due to UVB irradiation, was increased by pre-treatment of the blackberry fermented product, and the expression of MMP-1 and MMP-2, which was increased due to UVB irradiation, was decreased. was found (FIG. 3).
실시예 4. 블랙베리 발효물 처리에 따른 MAPK와 NFκB 활성 분석Example 4. Analysis of MAPK and NFκB Activity by Blackberry Fermentation Treatment
MAPK(Mitogen-activated protein kinase) 신호 전달의 경로는 면역 반응 조절, MMPs(matrix metalloproteinases) 발현, 염증 등을 조절하는 데 중요한 역할을 한다. 본 실시예에서는 웨스턴 블롯팅(Western blotting)을 이용하여 블랙베리 발효물(FBB)의 MAPK 및 NFκB 활성을 억제하는지 관찰하였다. 그 결과, 도 4에 개시한 바와 같이 UVB를 단독 조사하였을 때 NFκB, ERK(extracellular signal-regulated kinase), JNK(c-Jun N-terminal kinases) 및 p38 단백질의 인산화 활성이 증가하였으나, 본 발명의 블랙베리 발효물을 전처리한 경우에 ERK, JNK, p38 및 NFκB의 인산화가 효과적으로 억제되었다. 반면에 블랙베리 추출물을 전처리하였을 때에는 MAPKs 및 NFκB의 인산화 수준 변화가 없었다. 이와 같은 결과는 블랙베리 발효물의 자외선에 의한 피부손상의 개선효과가 MAPKs 및 NFκB의 신호전달경로 억제를 통하여 이루어지는 것으로 판단된다.Mitogen-activated protein kinase (MAPK) signaling pathway plays an important role in regulating immune response, matrix metalloproteinases (MMPs) expression, and inflammation. In this example, it was observed whether the MAPK and NFκB activities of blackberry fermentation (FBB) were inhibited using Western blotting. As a result, phosphorylation activity of NFκB, extracellular signal-regulated kinase (ERK), c-Jun N-terminal kinases (JNK), and p38 proteins was increased when UVB was alone irradiated as shown in FIG. Phosphorylation of ERK, JNK, p38 and NFκB was effectively inhibited when the blackberry ferment was pretreated. On the other hand, there was no change in the phosphorylation level of MAPKs and NFκB when the blackberry extract was pretreated. According to these results, it is judged that the improvement effect of the blackberry fermented product on skin damage caused by ultraviolet rays is achieved through inhibition of the signaling pathways of MAPKs and NFκB.
실시예 5. 모델 마우스에서 블랙베리 발효물 처리에 따른 자외선에 의한 피부주름 개선 효능Example 5. Efficacy of skin wrinkle improvement by ultraviolet light according to blackberry fermented product treatment in model mice
마우스의 등쪽 피부에서 UVB 조사에 의한 주름 형성에 블랙베리 발효물이 미치는 영향을 확인하였다. 그 결과, 도 5A에 개시한 바와 같이 4주간의 UVB 노출에 의해 마우스 피부의 주름 형성이 현저히 증가하였으며, 블랙베리 추출물을 전처리하더라도 주름 형성 변화에는 아무런 영향이 없음을 확인하였다. 반면에, 본 발명의 블랙베리 발효물을 전처리하고 UVB를 조사하였을 때, 주름 형성이 현저히 감소되는 것을 확인할 수 있었다. UVB 조사는 과도한 표피 증식과 피부 두께를 증가시켜 피부 거칠기를 유도한다고 알려져 있다. 따라서 UVB 조사 후 피부의 두께를 측정하기 위해, H&E(hematoxylin-eosin) 염색을 통해 조직학적 검사를 수행하였다. 그 결과, 대조군(CON)과 비교하여 UVB 단독 처리군에서 각질형성세포의 증식 및 비대에 의해 표피의 두께가 현저하게 증가하였으나, 본 발명의 블랙베리 발효물을 전처리한 경우에 표피의 두께가 현저히 감소하였고 블랙베리 추출물에 비해 유의하게 감소한 것을 확인할 수 있었다(도 5B 및 5C).The effect of fermented blackberry on the formation of wrinkles by UVB irradiation in the dorsal skin of mice was confirmed. As a result, as shown in FIG. 5A , it was confirmed that the wrinkle formation of the mouse skin was significantly increased by UVB exposure for 4 weeks, and even if the blackberry extract was pre-treated, there was no effect on the wrinkle formation change. On the other hand, when the blackberry fermented product of the present invention was pre-treated and irradiated with UVB, it was confirmed that the wrinkle formation was significantly reduced. UVB irradiation is known to induce skin roughness by excessive epidermal proliferation and increase in skin thickness. Therefore, in order to measure the thickness of the skin after UVB irradiation, a histological examination was performed through hematoxylin-eosin (H&E) staining. As a result, compared with the control group (CON), the thickness of the epidermis was significantly increased due to proliferation and hypertrophy of keratinocytes in the UVB-only treatment group, but the thickness of the epidermis was significantly increased when the blackberry fermented product of the present invention was pretreated. decreased and it was confirmed that it was significantly reduced compared to the blackberry extract ( FIGS. 5B and 5C ).
실시예 6. 모델 마우스에서 블랙베리 발효물 처리에 따른 프로콜라겐 및 MMPs 합성능 변화Example 6. Changes in procollagen and MMPs synthesis ability according to blackberry fermentation in model mice
MMP-1(Matrix metalloproteinases-1)은 콜라겐 섬유의 분해를 유발하여 콜라겐 합성을 감소시킨다고 알려져있다. 프로콜라겐(Procollagen)은 피부의 섬유아세포에 의해 생성되며 UVB 조사로 인해 발현이 감소되어 광노화의 원인이 된다. 모델 마우스의 혈청 및 조직 균질액을 대상으로 UVB 노출 후 MMP-1 및 프로콜라겐의 합성능을 확인하기 위해 ELISA 키트를 사용하여 측정하였다. 그 결과, 혈청 및 조직 균질액에서 UVB 조사는 MMP-1 생성을 유의하게 증가시켰고, 본 발명의 블랙베리 발효물(FBB)을 전처리하고 UVB를 조사한 경우 MMP-1 생성을 현저히 감소시켰다. 또한, 블랙베리 추출물(BB) 처리군과 블랙베리 발효물(FBB) 처리군 간의 유의한 차이가 있었다. 프로콜라겐 생성 측정 결과에서도 마찬가지로 UVB 조사로 인해 유의하게 감소한 프로콜라겜 함량이 블랙베리 발효물(FBB)을 전처리하였을 때 증가한 것을 알 수 있었으며, 블랙베리 추출물(BB) 처리군과 블랙베리 발효물(FBB) 처리군 간의 유의한 차이가 있었다(도 6).Matrix metalloproteinases-1 (MMP-1) is known to decrease collagen synthesis by inducing the breakdown of collagen fibers. Procollagen is produced by fibroblasts of the skin and its expression is reduced due to UVB irradiation, which causes photoaging. In order to confirm the synthesis ability of MMP-1 and procollagen after UVB exposure to the serum and tissue homogenate of a model mouse, it was measured using an ELISA kit. As a result, UVB irradiation in serum and tissue homogenates significantly increased MMP-1 production, and when the blackberry fermented product (FBB) of the present invention was pre-treated and irradiated with UVB, MMP-1 production was significantly reduced. In addition, there was a significant difference between the blackberry extract (BB) treatment group and the blackberry fermented product (FBB) treatment group. Similarly, in the measurement result of procollagen production, it was found that the procollagem content, which was significantly reduced due to UVB irradiation, increased when the blackberry fermented product (FBB) was pretreated, and the blackberry extract (BB) treated group and the blackberry fermented product ( There was a significant difference between the FBB) treatment groups (FIG. 6).
또한, 무모 마우스의 등쪽 피부 조직에서 UVB 조사 후 면역조직화학적 변화를 관찰한 결과, 도 7에 개시한 바와 같이 UVB 조사에 의해 MMP-1 발현이 증가된 반면, 블랙베리 발효물(FBB) 전처리에 의해 감소되는 것을 확인하였으며, 프로콜라겐 및 MMPs 단백질을 정량한 결과에서도, UVB 조사로 인해 MMP-1 및 MMP-2의 함량은 증가되고 프로콜라겐 1 및 3의 함량은 감소하였으나, 블랙베리 발효물(FBB)을 전처리함으로써 MMP-1 및 MMP-2의 함량은 감소되고 프로콜라겐 1 및 3의 함량은 증가한 것을 확인하였으며, 블랙베리 추출물에 비해 블랙베리 발효물을 전처리한 경우에 프로콜라겐 및 MMPs의 함량 변화에 유의한 차이가 있다는 것을 확인하였다.In addition, as a result of observing immunohistochemical changes after UVB irradiation in the dorsal skin tissue of hairless mice, MMP-1 expression was increased by UVB irradiation as shown in FIG. 7 , whereas blackberry fermented (FBB) pretreatment In the results of quantification of procollagen and MMPs proteins, the contents of MMP-1 and MMP-2 increased and the contents of
실시예 7. 모델 마우스에서 블랙베리 발효물 처리에 따른 MAPK 및 NFκB pathway 단백질 발현 분석Example 7. Analysis of MAPK and NFκB pathway protein expression following blackberry fermentation in model mice
MAPK(Mitogen-activated protein kinase) 신호 전달의 경로는 면역 반응 조절, MMPs(matrix metalloproteinases) 발현, 염증 등을 조절하는 데 중요한 역할을 한다. 본 실시예에서는 웨스턴 블롯팅(Western blotting)을 이용하여 블랙베리 발효물(FBB)이 마우스 피부조직에서 MAPK 및 NFκB 활성을 억제하는지 관찰하였다. 그 결과, 도 8에 개시한 바와 같이 UVB 조사 후에 ERK(extracellular signal-regulated kinase), JNK(c-Jun N-terminal kinases) 및 p38 단백질의 인산화 수준이 증가하였으나, 블랙베리 발효물(FBB)을 전처리하고 UVB를 조사하였을 때에는 증가된 ERK, JNK 및 p38 단백질의 인산화 수준이 현저하게 감소되었으며, 블랙베리 추출물(BB) 보다 효능이 우수한 것을 확인하였다. 또한, iNOS(Inducible nitric oxide synthase) 및 COX-2(cyclooxygenase-2)의 단백질 발현은 UVB 조사로 인해 유의하게 증가하였으나, 블랙베리 발효물(FBB)을 전처리함으로써 증가된 iNOS 및 COX-2의 발현량이 감소되었으며 블랙베리 추출물(BB) 및 블랙베리 발효물(FBB) 군간의 유의한 차이가 있는 것을 확인하였다(도 9A). The pathway of mitogen-activated protein kinase (MAPK) signaling plays an important role in regulating immune responses, matrix metalloproteinases (MMPs) expression, and inflammation. In this example, it was observed whether fermented blackberry (FBB) inhibited MAPK and NFκB activity in mouse skin tissues using Western blotting. As a result, phosphorylation levels of ERK (extracellular signal-regulated kinase), JNK (c-Jun N-terminal kinases), and p38 proteins were increased after UVB irradiation as shown in FIG. 8, but blackberry fermented (FBB) When pre-treatment and UVB irradiation were performed, the phosphorylation levels of the increased ERK, JNK and p38 proteins were significantly reduced, and it was confirmed that the efficacy was superior to that of the blackberry extract (BB). In addition, the protein expression of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) was significantly increased due to UVB irradiation, but the expression of iNOS and COX-2 increased by pretreatment of blackberry fermented product (FBB) The amount was reduced and it was confirmed that there was a significant difference between the blackberry extract (BB) and blackberry fermented product (FBB) groups (FIG. 9A).
한편, MAPKs의 활성화는 NFκB(nuclear factor kappa light chain enhancer of activated B cell)와 같은 여러 전사인자의 활성화를 일으킨다고 알려져 있다. 블랙베리 발효물(FBB)은 UVB 조사로 인해 증가된 NFκB 및 IκBα(nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha)의 인산화 수준을 효과적으로 감소시켰다(도 9B).On the other hand, activation of MAPKs is known to cause activation of several transcription factors, such as NFκB (nuclear factor kappa light chain enhancer of activated B cell). Fermented blackberry (FBB) effectively reduced phosphorylation levels of NFκB and IκBα (nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha) increased by UVB irradiation (FIG. 9B).
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020200013016A KR102405511B1 (en) | 2020-02-04 | 2020-02-04 | Composition for skin regeneration, improvement or treatment damaged by ultraviolet light containing blackberry fermented product as an active ingredient |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020200013016A KR102405511B1 (en) | 2020-02-04 | 2020-02-04 | Composition for skin regeneration, improvement or treatment damaged by ultraviolet light containing blackberry fermented product as an active ingredient |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20210099317A KR20210099317A (en) | 2021-08-12 |
KR102405511B1 true KR102405511B1 (en) | 2022-06-07 |
Family
ID=77314685
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020200013016A KR102405511B1 (en) | 2020-02-04 | 2020-02-04 | Composition for skin regeneration, improvement or treatment damaged by ultraviolet light containing blackberry fermented product as an active ingredient |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR102405511B1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102496500B1 (en) * | 2022-06-24 | 2023-02-07 | 주식회사 쌤시크코스메틱 | Cosmetic composition comprising hydroxydecyl ubiquinone, vegetable squalane and natural mixed extract, and method for preparing the same |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101970628B1 (en) | 2017-09-14 | 2019-04-22 | 주식회사 코리아나화장품 | Cosmetic Composition Containing Extracts of Blackberry and Cranberry |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101983041B1 (en) * | 2017-08-08 | 2019-05-29 | 신홍식 | Fermentation method of lactic acid bacteria using berry and its use |
-
2020
- 2020-02-04 KR KR1020200013016A patent/KR102405511B1/en active IP Right Grant
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101970628B1 (en) | 2017-09-14 | 2019-04-22 | 주식회사 코리아나화장품 | Cosmetic Composition Containing Extracts of Blackberry and Cranberry |
Non-Patent Citations (1)
Title |
---|
Divya et al., Toxicology and Applied Pharmacology. 2015, Vol. 2, Issue 1, pp. 92-99 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102496500B1 (en) * | 2022-06-24 | 2023-02-07 | 주식회사 쌤시크코스메틱 | Cosmetic composition comprising hydroxydecyl ubiquinone, vegetable squalane and natural mixed extract, and method for preparing the same |
Also Published As
Publication number | Publication date |
---|---|
KR20210099317A (en) | 2021-08-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101776071B1 (en) | Composition containing red sword bean extract for anti-aging and whitening | |
KR101452770B1 (en) | Cosmetic composition comprising lactobacillus fermented solution having anti-oxidation, whitening and anti-wrinkle effect | |
KR101851284B1 (en) | Composition for Preventing Skin Aging and Improving Skin Wrinkle Comprising Extract of Perilla Leaf | |
Cha et al. | Inhibitory effect and mechanism on melanogenesis from fermented herbal composition for medical or food uses | |
KR102405511B1 (en) | Composition for skin regeneration, improvement or treatment damaged by ultraviolet light containing blackberry fermented product as an active ingredient | |
KR20100121352A (en) | A composition comprising complex crude drug extract for anti-aging and improvement of skin | |
KR20180040756A (en) | Skin whitening composition comprising an extract of coixlachryma-jobi var. mayuen | |
KR102608602B1 (en) | Composition for improving skin wrinkle by ultraviolet rays using AHG | |
KR101863053B1 (en) | Composition with the extract of roasted Schisandra chinensis for improvement of skin wrinkle | |
KR101483872B1 (en) | Composition for anti-wrinkling comprising fractions from leaves of quercus mongolica | |
KR20200098153A (en) | Composition for preventing or improving of skin wrinkle or skin photo-aging comprising fermented extract of Dendropanax morbifera and purple sweet potato as an active ingredient | |
KR102456797B1 (en) | Composition for preventing, improving or treating macular degeneration comprising fermented liquor of paprika as effective component | |
KR102462347B1 (en) | Cosmetic composition for improving skin barrier function and anti-wrinkle effects comprising fermented eggplant extract as an active ingredient | |
KR100596316B1 (en) | Composition of health functional food to support skin beauty and antiaging | |
KR101579500B1 (en) | Skin whitening composition comprising an extract obtained from roots of coix lachryma-jobi var. mayuen | |
KR101621499B1 (en) | Composition for increasing matrix metalloproteinase expression comprising Euphorbia lathyris extract and use thereof | |
Kim et al. | Anti-aging activities of Pyrus pyrifolia var culta plant callus extract | |
KR101995384B1 (en) | Composition for skin whitening and anti-oxidation comprising fermented Gynura procumbens as effective component | |
KR20220110931A (en) | Compositions for preventing, improving or treating periodontal disease containing dendropanax morbifera lev. extracts | |
KR20160068316A (en) | Skin whitening composition comprising an extract obtained from phellodendron amurense rupr. | |
KR101526435B1 (en) | Compositions for skin-whitening comprising extract of Vitis amurensis ruprecht | |
KR20200066443A (en) | A pharmaceutical composition for preventing or treating aging or an aging-related disease comprising an anthocyanin-polysaccharide complex as an active ingredient | |
KR102250928B1 (en) | Cosmetic composition containing Trapa japonica Flerov callus extracts | |
KR102104803B1 (en) | Composition Comprising Gingenoside F2 and 4-α-D-Glucopyranosyloxy Benzyl Alcohol for Preventing or Improving Skin Wrinkle as Active Ingredient | |
KR102489463B1 (en) | Composition for whitening comprising extract of microwave treated Dendropanax morbifera |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
E601 | Decision to refuse application | ||
X091 | Application refused [patent] | ||
AMND | Amendment | ||
X701 | Decision to grant (after re-examination) | ||
GRNT | Written decision to grant |